Today, December 6, the online pharmacy Apotea starts trading on Nasdaq Stockholm. The share is traded on the Midcap segment with the ticker APOTEA. The subscription price has been set at SEK 58 per share, corresponding to a market capitalization of all shares of SEK 6,036 million.

The offering comprises 28.18 million existing ordinary shares, representing 27.4 percent of the shares in the company, sold by the current shareholders Laulima, Alecta Tjänstepension, SEB Life International Assurance Company, Neudi Kapital and Creades.

Apotea will not raise any capital, and will therefore not receive any proceeds, in connection with the offer.

There is also an over-allotment option to sell up to 4.22 million additional shares at the subscription price, corresponding to 15 percent of the number of shares in the offering. Upon full exercise of the over-allotment option, the offer comprises a maximum of 32.41 million shares, corresponding to 31.1 percent of the shares in the company.

The offer corresponds to SEK 1,635 million if fully subscribed and SEK 1,880 million if the over-allotment option is fully exercised.

Anchor investors are funds managed by Capital Group, Nordea Asset Management, WCM Investment Management, Ramsbury Invest and AMF Aktiefond Småbolag, which have committed to acquire shares in the offering at the subscription price for a total amount of SEK 975 million.